Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer Biomet Lands Medtronic Exec As Its New CEO

Executive Summary

The orthopedic giant hired a well-respected medtech industry veteran as its new CEO, leading to some seat-jumping within Medtronic's executive ranks.

You may also be interested in...



Zimmer Biomet Continues Turnaround Lead by ROSA Robot

Zimmer Biomet’s net sales were up 1.2% year-over-year in the second quarter. CEO Bryan Hanson said the ROSA Knee robotic surgery system is performing even better than expected since it launched earlier this year, and is expected to be an important revenue-driver in the future.

Exec Chat: Zimmer Biomet's EMEA Head On Facing The New Reality In Health Care

As Katarzyna Mazur-Hofsäss approaches her fifth anniversary as head of Zimmer Biomet's EMEA division, she chats with Medtech Insight about her concerns as medical device companies operating in Europe try to cope with the new regulatory environment and how the orthopedics giant is responding to new demands from health-care providers. 

Global Approvals Analysis: Emerging Markets Drive Volume Of OUS Approvals

The numbers of medical device approvals were up in most regions outside the US and the biggest surge, by percentage, was in approvals from emerging markets and the so-called BRIC countries. It remains to be seen if the trend will continue in 2018, but many companies are already counting on important non-US approvals coming in the next year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel